Moving Promising Technologies off the Shelf: Commentary from the Private Sector Chris Wagner President & CEO Sirius Genomics

Background 20+ years of commercialization in applied science – Pharmaceutical & Biotechnology – Diagnostics – Medical devices – Large companies & small companies – Pre human to post commercial Commercialized products in Canada, USA, Europe, Asia Direct P&L responsibility for >$22 B in cumulative revenues CEO Sirius Genomics BOD and SAB for several research based organizations

My Practical Experience Commercial orientation from day one is a must If commercial is correct technical risk is the only risk Commercial orientation = customer orientation Companies usually commercialize products not universities or governments Companies are either the Customer or a good proxy Products from science are global not just Canadian Commercial orientation is difficult for some researchers; often not willing to walk away from an idea

Is the Issue Properly Framed Limited success of Canadian research translation TCOS framework captures success components Global nature of scientific commercialization should be more explicit Customer centric thinking should be emphasized Private sector involvement should be emphasized

Policy Options Moving Forward Scientists who integrate TCOS will be more successful in moving products off the shelf Enhance TCOS framework with: global focus, customer centric, company or end user involvement Consider “entrepreneur in residence” model Consider a link between continued funding and legitimate adoption of TCOS